GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2007

LigoCyte and Biogen Idec Ally to Develop Anti-CD103 Drugs

  • LigoCyte Pharmaceuticals inked a partnership with Biogen Idec to develop therapies targeting CD103 for the treatment of chronic inflammatory diseases.

    CD103 is a alphaE-beta7 integrin that has been implicated in the activation, homing, and retention of lymphocytes that mediate inflammatory diseases affecting mucosal regions of the intestine, skin, and lungs.

    LigoCyte will receive milestone payments on the successful development of drug candidates. The collaboration includes an opportunity for codevelopment, copromotion, and sharing of profits resulting from commercialized products.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?